Business
Objections to a COMPASS psilocybin synthesis patent have been rejected; Usona’s new efficient technique cannot be patented.
In this week’s Trip Report, England’s National Institute for Health and Care Excellence rejects Spravato, some of the most prominent names in psychedelics will gather for Psych Congress 2020, and more.
David Bronner talks about his company’s 10 year financial commitment to the Multidisciplinary Association for Psychedelic Studies, the importance of supporting MAPS’ nonprofit approach to MDMA research, Dr. Bronner’s “Heal Soul” campaign, and more.
Two companies are developing dissolvable strips to deliver psilocybin, the active ingredient in magic mushrooms.
A Salt Lake City doctor claims his method of using high dose intramuscular injections of ketamine is novel, but other ketamine clinicians say it’s not a new discovery.
Field Trip Collaborates with Jamaican University Researchers to Investigate New Psilocybin Therapies
The focus is on how psilocybin-producing mushrooms may generate a different effect than synthetic psilocybin.
It’s time for the psychedelic community to set high standards, say the cofounders in this exclusive video interview.
After canceling its main event, Burning Man is facing a $10 million budget shortfall for 2020 and appealing to its community for donations.
A patent granted to Compass Pathways is drawing attention to how pharmaceutical companies might end up owning forms of long-established psychedelic substances. Part 2 of a 3-part series.
Tactics used by Compass Pathways common to pharma companies pose ethical questions for the emerging psychedelics industry. Part one of a three-part series.
